VeriChip Corporation Announces American Medical Association Recommends Implantable RFID Devices to Improve the Safety and Efficiency of Patient Care: As Only Company With FDA-Cleared RFID Implantable Microchip, AMA's Recommendation Expected to Enhance Marketing Efforts
VeriChip Corporation (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, announced today the American Medical Association's (AMA) Council on Ethical and Judicial Affairs has adopted a policy stating that implantable radio frequency identification (RFID) devices may help to identify patients, thereby improving the safety and efficiency of patient care, and may be used to enable secure access to patient clinical information. VeriChip has the only FDA-cleared RFID implantable microchip for patient identification and health information purposes. VeriChip anticipates that the AMA's recommendation will enhance the Company's marketing efforts by accelerating the adoption by hospitals of the VeriMed Patient Identification System and increasing the profile of the VeriChip among the medical community.
DELRAY BEACH, Fla. (PRWEB) June 27, 2007
About VeriChip
VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. The Company recently began marketing its VeriMed(TM) Patient Identification System, a passive RFID system for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.
VeriChip Corporation is majority-owned by Applied Digital Solutions Inc. (NASDAQ:ADSX), which also owns a majority position in Digital Angel Corporation (AMEX:DOC). For more information on VeriChip, please call 1-800-970-2447, or email info@verichipcorp. com. Additional information can be found online at http://www. verichipcorp. com (http://www. verichipcorp. com).
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
